Partially hydrolysed guar gum (PHGG) appeared to be efficacious in patients with irritable bowel syndrome-associated chronic constipation.
A 66-year-old patient enters the ER with persistent fever, night sweats and significant weight loss. He is admitted with the diagnosis of “persistent bronchopneumonia”...
An accelerated treatment algorithm appeared to benefit patients with large pancreatic WON in terms of length-of-stay in the hospital and major complications.
A study found faecal microbiota transplantation was safe and non-inferior to vancomycin in patients with primary Clostridioides difficile infections.
Etrasimod was associated with favourable outcomes and tolerability in patients with moderately to severely active CD in a phase 2 trial extension.
Key issues were discussed at the UEG Week related to current approaches to diagnostics, treatment and practical takeaways of malabsorption syndromes.
A special congres session took a critical look at common errors in the management of lower gastrointestinal conditions, providing insights for clinical practice.
Hepatobiliary and disease guidelines and updates were discussed during a session on prancreas-related cancer, exocrine insufficiency, cysts, and NASH.
A meta-analysis showed that HS familial cases are associated with higher cardiovascular diseases, hyperlipidaemia, and diabetes mellitus risk.
Post-hoc analysis of the THRIVE-AA1 and THRIVE-AA2 trials showed satisfaction in the THRIVE-AA1 and THRIVE-AA2 trials as early as week 12.
Povorcitinib led to a sustained reduction of pruritus and skin lesions in prurigo nodularis in a randomised-controlled phase 2 study.
Continuing bimekizumab for 2 years led to maintenance of various HiSCR and International Hidradenitis Suppurativa Severity Score System (IHS4) scores.
Orismilast demonstrated higher rates of Investigator Global Assessment of 0/1 at week 16 compared with placebo in the phase 2b ADESOS trial.
A comparison of topical delgocitinib with systemic alitretinoin for treating patients with chronic hand eczema (CHE) favoured the pan-JAK inhibitor.
Delgocitinib was associated with a reduction in interferon gamma (IFN-γ), chemokine ligand (CXCL)9, and CXCL10 in the treatment of FFA.
A comprehensive analysis from the German Psoriasis Registry (PsoBest) highlights the evolution of systemic drug use for psoriasis over the past 15 years.
A study including data from over 30,000 participants revealed that early onset of atopic dermatitis (AD) leads to a psychosocial burden throughout adult life.
Withdrawing nemolizumab led to an 8-fold increase in the likelihood of a prurigo nodularis (PN) relapse compared with uninterrupted therapy.
A combination of eye-tracking tests could help to speed up the diagnostic process and make it more efficient, according to the authors.
A single dose of 750 mg imsidolimab yielded a GPPPGA score of clear or almost clear in over half of the participants with GPP after 4 weeks.